# Strain-dependent modifiers exacerbate familial leukemia caused by GATA1-deficiency

**Authors:** Ikuo Hirano, Kanako Abe, James Douglas Engel, Masayuki Yamamoto, Ritsuko Shimizu

PMC · DOI: 10.1186/s40164-024-00491-w · 2024-02-26

## TL;DR

This study shows that genetic background influences leukemia development in mice with a GATA1 deficiency, with some strains accelerating the disease.

## Contribution

The study identifies strain-specific genetic modifiers that influence leukemia progression in Gata1-deficient mice.

## Key findings

- C57BL/6J and 129X1/SvJ backgrounds significantly expedite leukemia onset in Gata1.05/X mice.
- Leukemia manifests in autosomal dominant patterns in 129X1/SvJ and autosomal recessive in C57BL/6J backgrounds.
- Genetic modifiers reshape leukemia outcomes based on gene signatures in Gata1-deficient mice.

## Abstract

GATA1 plays a critical role in differentiation, proliferation, and apoptosis during erythropoiesis. We developed a Gata1 knock-down allele (Gata1.05) that results in GATA1 expression at 5% of endogenous level. In female mice heterozygous for both the Gata1.05 and wild-type alleles, we observed a predisposition to erythroblastic leukemia three to six months after birth. Since no male Gata1.05 progeny survive gestation, we originally maintained heterozygous females in a mixed genetic background of C57BL/6J and DBA/2 strains. Around 30% of these mice reproducibly develop leukemia, but the other subset did not develop leukemia, even though they harbor a high number of preleukemic erythroblasts. These observations prompted us to hypothesize that there may be potential influence of genetic determinants on the progression of Gata1.05-driven hematopoietic precursors to full-blown leukemia. In an initial examination of Gata1.05/X mice backcrossed into C3H/He, BALB/c, DBA/2, C57BL/6J and 129X1/SvJ strains, we discerned that the backgrounds of C57BL/6J and 129X1/SvJ significantly expedited leukemia onset in Gata1.05/X mice. Conversely, backgrounds of C3H/He, BALB/c and DBA/2 did not substantially modify the effect of the Gata1 mutation. This indicates the existence of genetic modifiers that accentuate Gata1.05 leukemogenesis. Subsequent cohort studies evaluated Gata1.05/X mice within mix backgrounds of BALB/c:129X1/SvJ and BALB/c:C57BL/6J. In these settings, Gata1.05-driven leukemia manifested in autosomal dominant patterns within the 129X1/SvJ background and in autosomal recessive patterns within C57BL/6J background. To the best of our knowledge, this study provides the inaugural evidence of genetic modifiers that can reshape the outcome based on leukemia-associated gene signatures.

The online version contains supplementary material available at 10.1186/s40164-024-00491-w.

## Linked entities

- **Genes:** GATA1 (GATA binding protein 1) [NCBI Gene 2623]
- **Diseases:** erythroblastic leukemia (MONDO:0017858)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Gata1 (GATA binding protein 1) [NCBI Gene 14460] {aka Gata-1, Gf-1, eryf1}
- **Diseases:** familial leukemia (MESH:D007938), erythroblastic leukemia (MESH:D004915)
- **Species:** Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** /c — Mus musculus (Mouse), Hepatocellular carcinoma of the mouse, Cancer cell line (CVCL_9103), BALB/c:129X1 — Homo sapiens (Human), Induced pluripotent stem cell (CVCL_VD22), /6J — Homo sapiens (Human), Cutaneous melanoma, Cancer cell line (CVCL_W797), DBA — Mus musculus (Mouse), Finite cell line (CVCL_6496)

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC10895851/full.md

---
Source: https://tomesphere.com/paper/PMC10895851